Shaperone announced on the 23rd that it has applied for a patent to prove the correlation between NuGel, an atopic dermatitis treatment under development, and biomarkers (biological markers). The patent is the result of analyzing the data of phase 2 patients with atopic dermatitis in Korea and confirming that biomarkers in the blood can be effectively used to predict the treatment reactivity of atopic dermatitis patients to NuGel. It is also a new technology that has revealed that the biomarkers can be used in Companion Diagnostics, which is required to maximize the therapeutic effect.

Until now, most of the development of biomarkers for companion diagnosis has been focused on the field of anticancer dr